Evidence map›Paper›PMID 33841408›Full record

ArticleFrontiers in immunology2021

Glomerular Immune Deposition in MPO-ANCA Associated Glomerulonephritis Is Associated With Poor Renal Survival.

Wei Lin, Chanjuan Shen, Yong Zhong, Joshua D Ooi, Peter Eggenhuizen, Ya-Ou Zhou, Hui Luo, Jing Huang, Jin-Biao Chen, Ting Wu and 9 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. The complement system in autoimmune diseases: pathogenesis, diagnostic markers, and therapeutic strategies.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  13. Review
  14. Article
  15. Presentation and progression of MPO-ANCA interstitial lung disease.Journal of translational autoimmunity · 2024
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Wei LinDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Chanjuan ShenDepartment of Hematology, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, China.
Yong ZhongDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Joshua D OoiCentre for Inflammatory Diseases, Monash University, Clayton, VIC, Australia.
Peter EggenhuizenCentre for Inflammatory Diseases, Monash University, Clayton, VIC, Australia.
Ya-Ou ZhouDepartment of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, China.
Hui LuoDepartment of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, China.
Jing HuangDepartment of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, China.
Jin-Biao ChenDepartment of Medical Records and Information, Xiangya Hospital, Central South University, Changsha, China.
Ting WuDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Ting MengDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Zhou XiaoDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Xiang AoDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Weisheng PengDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Rong TangDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Hongling YinDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Xiangcheng XiaoDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Qiaoling ZhouDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Ping XiaoDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNXiangya Hospital Central South University · CNMonash University · AUZhuzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Rapidly progressive glomerulonephritis caused by antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is typically characterized as pauci-immune glomerulonephritis. However, immune complex (IC) deposition in the glomerulus has been reported in a growing number of studies. Here, we assess the presence of glomerular immune deposits alongside renal outcome in myeloperoxidase (MPO)-ANCA associated glomerulonephritis (MPO-ANCA GN). Methods: Clinical and histopathologic characteristics of 97 patients with MPO-ANCA GN classified by renal biopsy from January 2008 to December 2019 were extracted retrospectively from electronic medical records. The extent of immune deposits in the kidney (C3, C4, C1q, IgA, IgG, IgM) at diagnosis were analyzed by immunofluorescence (IF). Patients were followed up for a median period of 15 months. The response to treatment and outcomes of renal and histological lesion changes were also assessed. Results: In our study, 41% (40/97) of patients showed positive IF (≥2+) for at least one of the six immunoglobulin or complement components tested. Patients with IC deposits showed higher levels of serum creatinine (p=0.025), lower platelet counts (p=0.009), lower serum complement C3 (sC3) (≤790 ml/L) (p=0.013) and serum IgG (p=0.018) than patients with pauci-immune (PI) deposition at diagnosis. End-stage renal disease was negatively associated with eGFR (HR 0.885, 95% CI 0.837 to 0.935, p<0.0001), platelet count (HR 0.996, 95% CI 0.992 to 1.000, p=0.046) and serum globulin (HR 0.905, 95% CI 0.854 to 0.959, p=0.001). Patients with lower sC3 levels showed a worse renal outcome than the patients with normal sC3 at diagnosis (p=0.003). Analysis of the components of the renal deposits found that patients with IgG deposits exhibited a poorer renal outcome compared to patients that were IgG negative (p=0.028). Moreover, Bowman's capsule rupture occurred less frequently in patients with IgM deposition compared with IgM negative counterparts (p=0.028). Vascular lesions and granuloma-like lesions had been seen more frequently in cases with IgA deposition than those without IgA deposition (p=0.03 and 0.015, respectively). Conclusion: In conclusion, patients with immune complex deposits in the kidney showed less platelet count, lower sC3 and sIgG levels, and higher serum creatinine levels. Patients with low sC3 at initial and with continued low sC3 during the treatment displayed a trend toward poorer kidney survival. Moreover, the IC group showed a worse renal outcome than the PI group, further enforcing the present strategy of introducing complement targeted therapies in AAV.

Indexed as

AdultAgedAntibodies, Antineutrophil CytoplasmicAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisBiopsyComplement System ProteinsCyclophosphamideDisease ProgressionDrug Therapy, CombinationFemaleFluorescent Antibody TechniqueGlomerulonephritisGlucocorticoidsHumansImmunoglobulin IsotypesImmunosuppressive AgentsAntibodies, Antineutrophil CytoplasmicComplement System ProteinsCyclophosphamideGlucocorticoidsImmunoglobulin IsotypesImmunosuppressive AgentsMPO protein, humanPeroxidaseAAV (ANCA-associated vasculitis)ANCAimmune depositsMPO – myeloperoxidasepauci-immune

Identifiers

PMID33841408
PMCPMC8027492
OpenAlexW3152208549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.